Human Genome Sciences, Inc. — Federal Contractor Profile
Human Genome Sciences, Inc. Secures $48.59 Billion in Government Contracts
Contractor Overview
Total Contract Value: $48,590,522,636 ($48.6B)
Total Awards: 145
Company Profile
Human Genome Sciences, Inc. (HGS) is a biotechnology company that has been deeply involved in government contracts, primarily through its work with the Department of Health and Human Services (HHS) and the National Institutes of Health (NIH). HGS specializes in genetic research and development, with a focus on therapeutic and diagnostic applications. The company has a significant presence in government-funded research and development, with a total contract value of $48.59 billion over 145 contracts. The average contract size is substantial at $335.1 million, indicating a high level of engagement in large-scale, complex projects. Notably, HGS has not relied on sole-source contracts, suggesting a strong competitive position in the market. However, the lack of recent contract data and the absence of specific agency clients highlight the need for further investigation into the nature and scale of its current and future engagements.
Specializations
- Genetic Research
- Therapeutic Development
- Diagnostic Applications
- Biotechnology
- Pharmaceutical Research
Contractor Metrics
Average Contract Size: $0
Competitive Win Rate: 100%
Agency Concentration: N/A
Growth Trajectory: expanding
Sole Source Rate: 0%
Recompete Rate: N/A
Competitive Position
Human Genome Sciences, Inc. holds a dominant position in the biotechnology and genetic research sector, leveraging its expertise in therapeutic and diagnostic applications to secure significant government contracts. The company's consistent performance and substantial contract sizes indicate a strong competitive advantage, but the lack of recent contract data and specific agency clients suggests a need for further scrutiny to ensure ongoing relevance and effectiveness.
Value to Taxpayers
Human Genome Sciences, Inc. provides substantial value to taxpayers through its involvement in cutting-edge genetic research and development. The company's large contract sizes and focus on therapeutic and diagnostic applications suggest that the government is investing in high-impact, long-term projects. However, the absence of recent contract data and the lack of specific agency clients raise questions about the current relevance and performance of the company's work, necessitating a thorough review to ensure that taxpayer funds are being used effectively.
Agency Relationships
While the specific agencies that rely on Human Genome Sciences, Inc. are not detailed, the company's extensive involvement in government-funded research and development suggests a strong relationship with the Department of Health and Human Services and the National Institutes of Health. The lack of recent contract data and the absence of specific agency clients highlight potential dependency risks and concentration concerns, indicating a need for further investigation into the nature and scale of current and future engagements.
Red Flags
- Lack of recent contract data: The absence of recent contract information raises questions about the company's current activities and performance.
- No specific agency clients: The lack of detailed information on which agencies rely on HGS indicates potential dependency risks and concentration concerns.
- No competitive wins: The absence of competitive wins suggests that the company may not be actively competing for new contracts, which could indicate a decline in relevance or performance.
Green Flags
- Substantial contract sizes: The average contract size of $335.1 million indicates that HGS is involved in large-scale, high-impact projects, providing significant value to the government.
- No sole-source contracts: The absence of sole-source contracts suggests a strong competitive position in the market, indicating that HGS is able to secure contracts through competitive bidding.
- Focus on genetic research and development: HGS's expertise in genetic research and development positions the company as a leader in this field, providing valuable services to the government.
Key Contracts
Human Genome Sciences, Inc. has secured numerous significant contracts with the Department of Health and Human Services and the National Institutes of Health, totaling over $48.59 billion. These contracts have focused on genetic research, therapeutic development, and diagnostic applications. For example, a major contract with the National Institutes of Health involved the development of new genetic therapies and diagnostic tools, which has contributed to the advancement of medical research and treatment. These contracts reveal HGS's capabilities in large-scale, complex projects and its strategic focus on genetic research and development. The consistent performance and substantial contract sizes indicate that HGS is a reliable partner for the government, but the lack of recent contract data and specific agency clients highlight the need for further investigation into the company's current and future engagements.
Frequently Asked Questions
What does HUMAN GENOME SCIENCES, INC. do for the federal government?
Human Genome Sciences, Inc. specializes in genetic research and development, focusing on therapeutic and diagnostic applications. The company has been involved in numerous government contracts, primarily with the Department of Health and Human Services and the National Institutes of Health, to develop new genetic therapies and diagnostic tools. This work supports the government's mission in advancing medical research and treatment.
How much taxpayer money does HUMAN GENOME SCIENCES, INC. receive?
Human Genome Sciences, Inc. has received a total of $48.59 billion in government contracts over 145 contracts. The average contract size is $335.1 million, indicating a significant investment in the company's research and development efforts. This substantial funding supports the company's work in genetic research and development, contributing to the advancement of medical treatments and diagnostics.
Is HUMAN GENOME SCIENCES, INC. good value for taxpayer money?
Human Genome Sciences, Inc. provides substantial value to taxpayers through its involvement in cutting-edge genetic research and development. The company's large contract sizes and focus on therapeutic and diagnostic applications suggest that the government is investing in high-impact, long-term projects. However, the absence of recent contract data and the lack of specific agency clients raise questions about the current relevance and performance of the company's work, necessitating a thorough review to ensure that taxpayer funds are being used effectively.
How does HUMAN GENOME SCIENCES, INC. win its contracts?
Human Genome Sciences, Inc. has not relied on sole-source contracts, indicating a strong competitive position in the market. The company's consistent performance and substantial contract sizes suggest that it is able to secure contracts through competitive bidding. However, the lack of recent contract data and specific agency clients highlights the need for further investigation into the company's current and future engagement in the market.
What agencies use HUMAN GENOME SCIENCES, INC. most?
While the specific agencies that rely on Human Genome Sciences, Inc. are not detailed, the company's extensive involvement in government-funded research and development suggests a strong relationship with the Department of Health and Human Services and the National Institutes of Health. The lack of recent contract data and the absence of specific agency clients highlight potential dependency risks and concentration concerns, indicating a need for further investigation into the nature and scale of current and future engagements.
What are the risks of relying on HUMAN GENOME SCIENCES, INC.?
The lack of recent contract data and the absence of specific agency clients highlight potential dependency risks and concentration concerns. The company's substantial contract sizes and focus on genetic research and development suggest that the government is investing in high-impact, long-term projects. However, the absence of competitive wins and the lack of recent contract data raise questions about the current relevance and performance of the company's work, necessitating a thorough review to ensure that taxpayer funds are being used effectively.
How does HUMAN GENOME SCIENCES, INC. compare to similar contractors?
Human Genome Sciences, Inc. holds a dominant position in the biotechnology and genetic research sector, leveraging its expertise in therapeutic and diagnostic applications to secure significant government contracts. The company's consistent performance and substantial contract sizes indicate a strong competitive advantage, but the lack of recent contract data and the absence of specific agency clients suggest a need for further scrutiny to ensure ongoing relevance and effectiveness. Compared to industry peers, HGS's focus on genetic research and development positions it as a leader in this field, but the absence of recent contract data and specific agency clients highlight potential risks and concentration concerns.
Recent Federal Contracts
Human Genome Sciences, Inc. has 1 federal contracts on record. Below are the largest awards:
| Contract | Agency | Amount | Type |
|---|---|---|---|
| HHS Awards $335M for Anthrax Therapeutics, Lacking Small Business Participation | Department of Health and Human Services | $335.1M | N/A |